DR-10624

N/A

Report date: 2026/04/07 20:00:20
First In Class

Base Information

Drug NameDR-10624
Drug Alias NameDR-10624DR10624
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionFibroblast growth factor 21 agonistsGlucagon receptor agonistsGlucagon-like peptide 1 receptor agonists
TargetsFibroblast growth factor 21Glucagon receptorGlucagon-like peptide 1 receptor
Therapy Area/IndicationsOverweightObesityHypertriglyceridemia +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesNew ZealandHong Kong +[4] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesZhejiang Doer Biologics Corp
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesZhejiang Doer Biologics Corp
Inactive CompaniesN/A
Active IndicationsOverweightObesityHypertriglyceridemia +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A